Search results for "registries"

showing 10 items of 615 documents

Low-risk isn’t no-risk: Perinatal treatments and the health of low-income newborns

2019

We investigate the effects of perinatal medical treatments on low-income newborns who are classified as low-risk. A policy rule in The Netherlands states that low-risk deliveries before week 37 should be supervised by physicians and later deliveries only by midwives with no physician present. This creates large discontinuities in the probability of receiving medical interventions only physicians are allowed to perform. Using a regression discontinuity design, we find that babies born slightly before the week-37 cutoff are significantly less likely to die than babies born slightly later. Our data suggest that physician supervision of birth reduces the likelihood of adverse events such as fet…

Low incomemedicine.medical_specialtyPerinatal carePsychological interventionPerinatal careGestational AgeRisk AssessmentMedical careMidwivesMedical interventions03 medical and health sciencesMedical treatmentsPregnancy0502 economics and businessFetal distressmedicineHumansRegistriesMortality050207 economicsAdverse effectPovertyNetherlandsQuality of Health CareObstetricsbusiness.industry030503 health policy & servicesHealth Policy05 social sciencesInfant NewbornParturitionPublic Health Environmental and Occupational Healthmedicine.diseasePerinatal CareBirthRegression discontinuity designFemalePrematurity0305 other medical sciencebusinessJournal of Health Economics
researchProduct

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

2016

IF 10.383; International audience; OBJECTIVES: Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.METHODS: In a French population-based cohort, we identified 844 patients aged >60 years at IBD diagnosis from 1988 to 2006, including 370 Crohn's disease (CD) and 474 ulcerative colitis (UC). We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM). Confidence interval (CI) was estimated assuming a Poisson-specific law for ra…

MESH: CarcinomaMaleNonmelanoma Skin-CancerInflammatory bowel disease0302 clinical medicineAdrenal Cortex HormonesAzathioprineMESH: IncidenceAge of OnsetAged 80 and overeducation.field_of_studyMESH: Middle AgedRheumatoid-ArthritisIncidenceGastroenterologyMESH: Follow-Up StudiesMESH: Anti-Inflammatory Agents Non-Steroidal3. Good health030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Immunosuppressive Agentsmedicine.medical_specialtyMESH: Age of OnsetMESH: Colitis Ulcerativedigestive systemMESH: Adrenal Cortex Hormones03 medical and health sciencesIntestinal NeoplasmsHumansCrohns-DiseaseeducationMESH: Intestinal NeoplasmsMESH: Protective FactorsMESH: AzathioprineAgedRetrospective StudiesMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphaMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesInflammatory Bowel Diseasesdigestive system diseasesLymphoproliferative DisordersMethotrexateMESH: Tumor Necrosis Factor-alphaColitis UlcerativeComplicationMESH: FemaleProspective Observational CohortTime FactorsMESH: RegistriesMESH: Proportional Hazards ModelsMaintenance TherapyMESH: Aged 80 and overMESH: Lymphoproliferative DisordersCrohn DiseaseMESH: Risk FactorsRisk FactorsNeoplasmsMESH: NeoplasmsRegistriesUlcerative-ColitisMesalamineMESH: AgedIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalMetaanalysisMiddle AgedhumanitiesMESH: MethotrexateFemaleFranceFrench PopulationColorectal NeoplasmsImmunosuppressive AgentsMESH: Myeloproliferative DisordersPopulationColorectal-CancerIncreased RiskInternal medicinemedicineProportional Hazards ModelsMyeloproliferative DisordersHepatologybusiness.industryMESH: Time FactorsCarcinomaCancerRetrospective cohort study[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MesalamineProtective FactorsMESH: MaleMESH: FranceAge of onsetbusinessMESH: Colorectal NeoplasmsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

The impact of the Eurofever criteria and the new Infevers MEFV classification in real life: results from a large international FMF cohort

2022

INTRODUCTION: New Eurofever/PRINTO classification criteria (EPCC) for Familial Mediterranean Fever (FMF) and other recurrent fevers have been recently developed, together with the classification of the pathogenicity of MEFV variants. OBJECTIVES: To evaluate the impact in real life of both the EPCC and INSAID pathogenicity classification of MEFV variants in the large international Eurofever FMF cohort. METHODS: Baseline demographic, genetic and clinical data of FMF patients included in the Eurofever registry were evaluated. The EPCC and the 2018 INSAID classification for MEFV variants were applied in all eligible FMF patients. RESULTS: Since November 2009, clinical information was available …

Male*Genetic analysis*Autoinflammatory diseasesPyrinFamilial Mediterranean fever*Classification criteriaCohort StudiesAnesthesiology and Pain MedicineRheumatologySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAMutation*Familial mediterranean feverHumansFemale*RegistryRegistriesAutoinflammatory diseases Classification criteria Familial mediterranean fever Genetic analysis Recurrent fevers Registry Cohort Studies Colchicine Female Humans Male Mutation Pyrin Registries Familial Mediterranean FeverColchicine*Recurrent fevers
researchProduct

Performance of Finnish biobanks in nationwide pulmonary carcinoid tumour research

2019

Finnish hospital-integrated biobanks administer millions of formalin-fixed paraffin-embedded tissue samples collected within the clinical diagnostics. According to the Finnish Biobank Act, these samples can be coupled with patients’ clinical follow-up data and the data retrieved from national health registries. We collected a nationwide pulmonary carcinoid tumour series from Finnish biobanks to study prognostic factors as well as to explore how the number of tumours found in the Finnish biobanks corresponds to the number of tumours registered by the Finnish Cancer Registry (FCR). Finnish biobanks identified 88% of the tumours registered by the FCR and were able to deliver 63%. The main reas…

Male0301 basic medicineLung NeoplasmsProliferation indexbiopankitDiseaseNeuroendocrine tumorskeuhkosyöpäPulmonary carcinoidTumour tissue0302 clinical medicineRARERegistriesINDEXFinlandBiological Specimen BanksOUTCOMESrare cancerSURGICAL RESECTIONGeneral MedicineMiddle AgedPrognosisBiobank3. Good healthbiobank030220 oncology & carcinogenesisMediastinal lymph nodeSURVIVALOriginal ArticleFemaleBURDENpulmonary carcinoidAdultmedicine.medical_specialty3122 CancersCarcinoid TumorPathology and Forensic Medicine03 medical and health sciencesInternal medicinemedicineQUALITYHumansharvinaiset tauditMolecular BiologyBiobankbusiness.industryRare cancerennusteetCell Biologymedicine.diseaseCarcinoma NeuroendocrineCancer registryPulmonary carcinoid tumour030104 developmental biologyEXPERIENCEprognosis3111 BiomedicinebusinessNEUROENDOCRINE TUMORSVirchows Archiv
researchProduct

Homozygous Familial Hypercholesterolemia in Spain Prevalence and Phenotype-Genotype Relationship

2016

Background— Homozygous familial hypercholesterolemia (HoFH) is a rare disease characterized by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) and extremely high risk of premature atherosclerotic cardiovascular disease. HoFH is caused by mutations in several genes, including LDL receptor ( LDLR ), apolipoprotein B ( APOB ), proprotein convertase subtilisin/kexin type 9 ( PCSK9 ), and LDL protein receptor adaptor 1 ( LDLRAP1 ). No epidemiological studies have assessed HoFH prevalence or the clinical and molecular characteristics of this condition. Here, we aimed to characterize HoFH in Spain. Methods and Results— Data were collected from the Spanish Dyslipidemia Regist…

Male0301 basic medicineOncologyLdl receptor geneApolipoprotein BLipid-lowering therapyFamilial hypercholesterolemia030204 cardiovascular system & hematologyCompound heterozygosity0302 clinical medicineAutosomal-dominant hypercholesterolemiaRisk FactorsEpidemiologyPrevalenceDiseaseRegistriesGenetics (clinical)Molecular EpidemiologybiologyhypercholesterolemiaHomozygoteDouble-blindMiddle AgedPhenotypeCardiovascular DiseasesApolipoprotein B-100allelesFemalelipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicineMutationsAdultGenetic MarkersHeterozygotemedicine.medical_specialtyInhibitorAdolescentPlacebo-controlled trialHyperlipoproteinemia Type IIlipidsYoung Adult03 medical and health sciencesInternal medicineGeneticsmedicineHumansGenetic Predisposition to DiseaseAlleleAdaptor Proteins Signal TransducingRecessive hypercholesterolemiaPCSK9registriesCholesterol LDLApolipoprotein-bmedicine.disease030104 developmental biologyEndocrinologyReceptors LDLSpainMutationLDL receptorbiology.proteinmutationDyslipidemia
researchProduct

Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study

2017

Background: Rare cancers pose challenges for diagnosis, treatments, and clinical decision making. Information about rare cancers is scant. The RARECARE project defined rare cancers as those with an annual incidence of less than six per 100 000 people in European Union (EU). We updated the estimates of the burden of rare cancers in Europe, their time trends in incidence and survival, and provide information about centralisation of treatments in seven European countries. Methods: We analysed data from 94 cancer registries for more than 2 million rare cancer diagnoses, to estimate European incidence and survival in 2000–07 and the corresponding time trends during 1995–2007. Incidence was calcu…

Male0301 basic medicinePathologypopulation-based registriesCancer Care Facilities; Delivery of Health Care; Europe; Female; Hospitalization; Humans; Incidence; Male; Neoplasms; Rare Diseases; Registries; Survival Rate; Oncology0302 clinical medicineNeoplasmsMedicineRegistriesmedia_commonTumors -- Treatment -- Europeeducation.field_of_studyRelative survivalIncidenceIncidence (epidemiology)RARECARE projectEuropeHospitalizationSurvival RateOncology030220 oncology & carcinogenesis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalemedicine.medical_specialtyHealth surveysPopulationSocio-culturaleCancer Care Facilities03 medical and health sciencesRare DiseasesSDG 3 - Good Health and Well-beingHumansmedia_common.cataloged_instanceCancer -- MortalityRisk factorEuropean unioneducationSurvival rateOncology cancer burden incidence rare cancerpopulation-based registriesrare cancers cancer registry RARECAREbusiness.industryRare cancerCancer -- Patients -- Long-term careCancer registry030104 developmental biologycancer burdenbusinessDelivery of Health CareDemographyRare disease
researchProduct

Pediatric bone tumors in Germany from 1987 to 2011: incidence rates, time trends and survival

2016

AbstractBackground: Malignant bone tumors are a rare group of childhood cancer.Materials and methods: This study describes incidence rates, survival probabilities, and time trends for 1831 children below 15 years of age with a bone tumor registered at the population-based German Childhood Cancer Registry between 1987 and 2011.Results: Overall age-standardized annual incidence rate (ASR) was 5.5 per million. Osteosarcomas (ASR 2.8) and Ewing tumors (ASR 2.6) were the most frequent diagnostic groups. The incidence of bone tumors overall tended to increase slightly over time by 0.7% each year on average. Thirty-nine of the bone tumor cases reported were subsequent primaries and not included in…

Male0301 basic medicinePediatricsmedicine.medical_specialtyTime FactorsAdolescentmedicine.medical_treatmentPopulationBone NeoplasmsSarcoma EwingAnnual incidence03 medical and health sciencesRare DiseasesSex Factors0302 clinical medicinemedicineHumansRadiology Nuclear Medicine and imagingRegistriesChildeducationSurvival analysisOsteosarcomaChemotherapyChildhood Cancer Registryeducation.field_of_studybusiness.industryTime trendsIncidenceIncidence (epidemiology)Age FactorsInfant NewbornInfantHematologyGeneral MedicineSurvival Analysis030104 developmental biologyOncologyChild Preschool030220 oncology & carcinogenesisFemalebusinessActa Oncologica
researchProduct

Differential models of twin correlations in skew for body-mass index (BMI)

2018

Background Body Mass Index (BMI), like most human phenotypes, is substantially heritable. However, BMI is not normally distributed; the skew appears to be structural, and increases as a function of age. Moreover, twin correlations for BMI commonly violate the assumptions of the most common variety of the classical twin model, with the MZ twin correlation greater than twice the DZ correlation. This study aimed to decompose twin correlations for BMI using more general skew-t distributions. Methods Same sex MZ and DZ twin pairs (N = 7,086) from the community-based Washington State Twin Registry were included. We used latent profile analysis (LPA) to decompose twin correlations for BMI into mul…

Male0301 basic medicinePhysiologyEntropyTwinsNormal Distributionlcsh:MedicineOverweight01 natural sciencesBody Mass IndexCorrelation010104 statistics & probabilityStatisticsTwins DizygoticMedicine and Health SciencesMixture distributionRegistrieslcsh:Science10. No inequalityMathematics2. Zero hungerMultidisciplinaryPhysicsMiddle AgedPhenotypePhysiological ParametersPhysical SciencesThermodynamicsFemalemedicine.symptomResearch ArticleStatistical DistributionsAdultMaterials by StructureMaterials ScienceSkewnessNormal distribution03 medical and health sciencesmedicineHumansObesity0101 mathematicsModels Geneticlcsh:RBody WeightBiology and Life SciencesTwins MonozygoticOverweightProbability TheoryProbability DistributionMixture modelTwin study030104 developmental biologySkewnessMixtureslcsh:QBody mass indexMathematicsDevelopmental BiologyPLOS ONE
researchProduct

Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry

2021

Abstract Objectives To investigate survival of IL-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective. Patients and methods Multicentre retrospective study analysing patients affected by the most common mAID treated with anakinra or canakinumab. Survival curves were analysed with the Kaplan-Meier method. Statistical analysis included a Cox-proportional hazard model to detect factors responsible for drug discontinuation. Results Seventy-eight patients for a total of 102 treatment regimens were enrolled. The mean treatment duration was 29.59 months. The estimated D…

Male0301 basic medicineTime FactorsSettore MED/16 - REUMATOLOGIAInterleukin-1beta0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaMonoclonalPharmacology (medical)RegistriesHumanizedmedia_commonIL-1 anakinra canakinumab innovative biotechnologies monogenic autoinflammatory disorders personalized medicinepersonalized medicineMiddle AgedPenetranceTreatment OutcomeAnakinraAntirheumatic AgentsAutoinflammationIL-1; anakinra; canakinumab; innovative biotechnologies; monogenic autoinflammatory disorders; personalized medicine; Adult; Antibodies Monoclonal Humanized; Antirheumatic Agents; Female; Follow-Up Studies; Hereditary Autoinflammatory Diseases; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult; RegistriesFemalemedicine.drugAdultDrugmedicine.medical_specialtymedia_common.quotation_subjectAntibodies Monoclonal HumanizedcanakinumabAntibodiesYoung Adult03 medical and health sciencesinnovative biotechnologiesRheumatologyInternal medicinemedicineHumansAdverse effectSurvival analysismonogenic autoinflammatory disordersRetrospective Studies030203 arthritis & rheumatologyAnakinraIL-1business.industryHereditary Autoinflammatory DiseasesRetrospective cohort studyInterleukin 1 Receptor Antagonist ProteinCanakinumab030104 developmental biologyObservational studybusinessFollow-Up Studies
researchProduct

Incidence, determinants and prognostic relevance of dyspnea at admission in patients with Takotsubo syndrome: results from the international multicen…

2020

AbstractClinical presentation of Takotsubo syndrome (TTS) may range from acute chest pain to dyspnea: the prognostic role of clinical onset is still controversial. Aim of this study was therefore to investigate the prognostic relevance of dyspnea at presentation in patients with TTS. We analyzed 1,071 TTS patients (median age 72 years, 90% female) enrolled in the international multicenter GEIST registry. Patients were divided according to the presence or absence of dyspnea at hospital admission, as clinically assessed by the accepting physician. The primary endpoint was occurrence of in-hospital complications defined as a composite of pulmonary edema, cardiogenic shock and death. Overall, 3…

Male0301 basic medicinemedicine.medical_specialtyShock CardiogenicCardiologylcsh:MedicinePulmonary EdemaArticleacute coronary syndrome03 medical and health sciences0302 clinical medicineRisk FactorsTakotsubo CardiomyopathyInternal medicinemedicineClinical endpointtakotsubo syndromeHumansRegistriesSigns and symptomslcsh:ScienceTakotsubo syndrome (TTS) chest pain.AgedMultidisciplinaryEjection fractionbusiness.industryIncidenceIncidence (epidemiology)Cardiogenic shockHazard ratiolcsh:RAtrial fibrillationtakotsubo syndrome; dyspnea; acute coronary syndromeOdds ratioMiddle AgedPrognosismedicine.diseasePulmonary edemaHospitalizationDyspnea030104 developmental biologyFemalelcsh:Qbusiness030217 neurology & neurosurgeryScientific Reports
researchProduct